List of Excipients in Branded Drug BOSLEY MD EXTRA STRENGTH FOR MEN

Generic Drugs Containing BOSLEY MD EXTRA STRENGTH FOR MEN

Company	Ingredient	NDC	Excipient
Scientific Hair Research LLC	minoxidil 5%	69113-002	ISOPROPYL ALCOHOL
Scientific Hair Research LLC	minoxidil 5%	69113-002	PROPYLENE GLYCOL
Scientific Hair Research LLC	minoxidil 5%	69113-002	WATER
Scientific Hair Research LLC	minoxidil 5%	69113-003	ISOPROPYL ALCOHOL
Scientific Hair Research LLC	minoxidil 5%	69113-003	PROPYLENE GLYCOL
Scientific Hair Research LLC	minoxidil 5%	69113-003	WATER

What are the Most Frequently-Used Excipients in BOSLEY MD EXTRA STRENGTH FOR MEN?

# Of NDCs	Excipient
2	ISOPROPYL ALCOHOL
2	PROPYLENE GLYCOL
2	WATER

BosleyMD Extra Strength for Men: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: September 24, 2026

BosleyMD Extra Strength for Men is an over-the-counter topical minoxidil product for male pattern hair loss. Its commercial position depends less on active-ingredient exclusivity and more on vehicle performance, scalp tolerability, packaging, channel access, and brand conversion. The core 5% minoxidil technology is mature and widely available under the FDA’s OTC hair-growth framework, leaving limited protection for the active ingredient itself.[1,2]

What is BosleyMD Extra Strength for Men?

BosleyMD Extra Strength for Men is marketed as a 5% minoxidil hair-regrowth treatment for men with androgenetic alopecia. The product category includes topical liquid solutions and foam presentations. The precise excipient profile depends on the marketed dosage form and package configuration.

Attribute	Commercial assessment
Active ingredient	Minoxidil 5%
Route	Topical scalp application
Regulatory category	OTC drug
Primary indication	Male pattern hair loss
Typical use	Twice daily for topical solution; foam directions may differ by label
Prescription status	Nonprescription
Biosimilar relevance	None
Orange Book relevance	Generally none for OTC monograph-compliant products
Core competitive set	Rogaine, store-brand minoxidil, telehealth brands, private-label products
Main differentiation levers	Vehicle, sensory profile, packaging, price, retail placement and clinical messaging

The product should be analyzed as a branded OTC formulation rather than as a drug with meaningful molecule-level exclusivity.

What excipients are used in BosleyMD Extra Strength for Men?

For the liquid 5% minoxidil category, the conventional inactive-ingredient system is based on alcohol, propylene glycol and purified water. These excipients provide solubilization, evaporation and delivery of minoxidil to the scalp. Foam products use a different system that can include fatty alcohols, surfactants, humectants, acids, water and hydrocarbon propellants.

Because BosleyMD products may be sold in more than one dosage form, the commercial excipient analysis should distinguish solution from foam.

Liquid solution excipient strategy

Excipient class	Typical function	Commercial implication
Ethanol or alcohol	Solvent and volatile vehicle	Improves drying but can increase stinging, dryness and flammability
Propylene glycol	Cosolvent and humectant	Supports minoxidil solubility; may cause irritation or contact dermatitis in some users
Purified water	Diluent	Controls vehicle balance and application feel
Minoxidil	Active drug	Requires adequate solubilization and uniform delivery

The solution vehicle is inexpensive, established and easy to manufacture. Its principal weakness is tolerability. Alcohol and propylene glycol can produce scalp dryness, burning, scaling or redness. These effects create an opportunity for differentiated vehicles, but also impose formulation constraints because minoxidil has limited aqueous solubility.

Foam excipient strategy

A 5% minoxidil foam generally uses a volatile propellant system and a nonaqueous or low-water matrix. The formula can contain:

• Cetyl alcohol and stearyl alcohol as structuring agents.
• Polysorbate 60 or related surfactants for dispersion and foam stability.
• Glycerin as a humectant.
• Citric acid or lactic acid for pH adjustment.
• Purified water as a controlled aqueous phase.
• Hydrocarbon propellants such as propane, butane or isobutane.

Foam avoids propylene glycol in many commercial formulations. That change can improve tolerability for users who experience irritation from liquid minoxidil. The tradeoff is higher packaging complexity, aerosol component cost, propellant-management requirements and transportation restrictions.

How does the BosleyMD excipient strategy compare with Rogaine and generic minoxidil?

The principal differentiation is dosage form and user experience, not the active ingredient.

Product type	Typical vehicle	Main advantage	Main weakness
5% minoxidil solution	Alcohol, propylene glycol, water	Low cost and simple manufacture	More dryness and irritation risk
5% minoxidil foam	Fatty alcohols, surfactants, humectants, propellants	Faster drying and often better cosmetic acceptance	Higher packaging and manufacturing cost
Generic solution	Usually alcohol, propylene glycol and water	Lowest price	Limited brand differentiation
Branded foam	Proprietary sensory and packaging presentation	Premium pricing opportunity	Strong substitution risk
Telehealth private label	Variable vehicle	Customer acquisition and subscription model	Dependence on outsourced manufacturing

Rogaine established the consumer category, but generic and store-brand products have commoditized minoxidil. BosleyMD can charge a premium only if the formulation, brand, consultation pathway or packaging provides a visible benefit to consumers.

What commercial opportunities exist for BosleyMD excipients?

The strongest opportunities are in tolerability, cosmetic elegance and adherence.

Propylene-glycol-free positioning

A propylene-glycol-free liquid or foam can target consumers who discontinue traditional solution because of irritation. This positioning has practical value because scalp tolerability directly affects treatment persistence. The product would need to maintain minoxidil solubility, dose uniformity and stability without relying on the conventional propylene glycol system.

Possible replacement strategies include:

• Alternative polyols.
• Solubilizing surfactants.
• Co-solvent blends.
• Microemulsion systems.
• Lipid-based or nano-dispersed vehicles.
• Anhydrous systems with modified evaporation profiles.

The key development risk is that a substitute solvent can create new irritation, odor, residue or instability problems.

Low-irritation formulation

A lower-irritation formulation could use reduced alcohol content, controlled pH, optimized surfactant selection and a more balanced humectant system. The commercial claim would need to remain within cosmetic or general product-performance boundaries unless supported by appropriate clinical data.

A product that reduces flaking and scalp tightness could support higher refill rates. The commercial value is therefore linked to adherence rather than only initial purchase.

Fast-drying and low-residue systems

Consumers often reject topical hair-loss products because they make hair greasy, stiff or difficult to style. Excipient optimization can improve:

• Drying time.
• Hair feel.
• Residue after application.
• Compatibility with styling products.
• Transfer to pillows, hats and clothing.
• Applicator control.

These characteristics are suitable targets for comparative consumer studies. They can support premium pricing even when the minoxidil concentration is identical to lower-priced alternatives.

Scalp and hair-type segmentation

A single vehicle does not serve all users equally. Commercial variants could target:

Segment	Formulation opportunity
Sensitive scalp	Alcohol-reduced, propylene-glycol-free or low-surfactant vehicle
Dry scalp	Humectant-balanced system with lower evaporative stress
Oily scalp	Fast-drying, low-residue vehicle
Curly or textured hair	Low-flake system with reduced stiffness and improved spreadability
Users with facial-hair spillover concerns	Precision applicator and localized delivery
Frequent travelers	Unit-dose, non-aerosol or compact packaging
Telehealth subscribers	Refill-friendly bottle, controlled dispensing and subscription packaging

These products would remain exposed to rapid substitution unless the formulation and packaging are protected by enforceable intellectual property.

What patents protect BosleyMD Extra Strength for Men?

The active minoxidil molecule is not a meaningful source of current product exclusivity. Minoxidil was developed decades ago, and the commercial market contains numerous generic 2% and 5% products.

Protection may instead arise from:

1. Formulation patents covering solvent ratios, particle size, delivery systems or stability.
2. Foam composition patents.
3. Applicator or dispensing patents.
4. Packaging patents.
5. Manufacturing-process patents.
6. Trademark rights associated with BosleyMD.
7. Trade secrets covering manufacturing parameters and quality controls.

A brand name does not establish patent protection. The relevant analysis requires a product-specific review of FDA labeling, public patent databases, assignment records and any litigation involving the manufacturer or licensee.

Does BosleyMD have Orange Book-listed patents?

A standard OTC minoxidil product marketed under the FDA monograph framework generally does not rely on an Orange Book-listed patent in the same manner as a new prescription drug. The Orange Book primarily addresses approved prescription and certain other NDA-based products, while OTC monograph products are regulated through a monograph pathway rather than an individual NDA exclusivity structure.[2,3]

Accordingly, a competitor generally would not confront a conventional Paragraph IV certification against BosleyMD merely by marketing a compliant generic minoxidil product.

When does BosleyMD lose exclusivity?

BosleyMD does not appear to have molecule-level exclusivity for 5% topical minoxidil. Market exclusivity is primarily commercial and contractual.

Exclusivity type	Likely status
New chemical entity exclusivity	Not applicable
Prescription NDA exclusivity	Not applicable to the standard OTC product
OTC monograph access	Available to qualifying competitors
Minoxidil active-ingredient patent	Expired or commercially irrelevant
Brand trademark	Potentially enforceable while maintained
Formulation patent	Product- and claim-specific
Distribution agreement	Contract-specific
Retail placement	Commercial rather than regulatory

The practical loss of exclusivity occurred when competing generic minoxidil products became broadly available. Current competition is therefore based on price, consumer trust, product experience, medical-adjacent services and distribution.

Are Paragraph IV challenges relevant to BosleyMD?

Paragraph IV litigation is generally not the principal competitive mechanism for an OTC monograph minoxidil product. A conventional ANDA applicant submits a Paragraph IV certification when seeking approval for a generic product referencing an NDA with listed patents. A monograph-compliant OTC minoxidil product does not typically require that pathway.

Competitive entry can occur through:

• OTC monograph compliance.
• Private-label manufacturing.
• Drug Facts labeling.
• State and federal facility compliance.
• Retailer or e-commerce distribution.
• Trademark clearance.

A competitor could still litigate formulation or packaging patents if those rights are asserted. That would be ordinary patent litigation, not necessarily Paragraph IV litigation.

What FDA regulatory status applies to BosleyMD?

Topical minoxidil products are subject to the FDA’s OTC framework for hair-growth products. The relevant regulation establishes conditions under which minoxidil products may be marketed without an approved prescription NDA.[1]

Key regulatory requirements include:

• Permitted active ingredient and concentration.
• Required directions and warnings.
• Appropriate Drug Facts labeling.
• Manufacturing under current good manufacturing practice requirements.
• Stability and quality controls.
• Packaging and tamper-related compliance where applicable.
• Adverse-event monitoring.
• Appropriate claims consistent with the product’s regulatory status.

A formulation change can trigger a new regulatory assessment if it affects active-ingredient delivery, labeling, dosage form, strength, safety profile or monograph compliance.

What manufacturing and IP barriers affect excipient innovation?

Minoxidil itself is inexpensive and widely available. Manufacturing barriers arise from formulation control and packaging execution.

Technical barriers

The main technical issues are:

• Maintaining complete minoxidil solubilization.
• Preventing crystallization during storage.
• Controlling viscosity and spreadability.
• Managing alcohol evaporation.
• Preserving foam structure.
• Controlling propellant fill and can performance.
• Maintaining dose uniformity.
• Avoiding nozzle clogging.
• Controlling microbial quality in water-containing systems.
• Ensuring compatibility between formula and package.

Intellectual-property barriers

A new excipient system may be protectable if it has:

• A novel composition.
• Defined concentration ranges.
• A demonstrated stability advantage.
• Improved deposition or delivery.
• Reduced irritation supported by testing.
• A distinctive foam or aerosol architecture.
• A specialized applicator or package.

Patent strength depends on claim breadth and the amount of prior art. Broad claims covering “a topical minoxidil composition with a solvent and water” would face substantial validity risk because the field is mature. Narrow claims directed to specific solvent ratios, particle characteristics, delivery systems or packaging configurations may be more defensible but provide limited freedom-to-operate coverage.

Which companies challenge BosleyMD commercially?

The major competitive threats are not likely to be patent challengers. They are substitute products and channels.

Competitor group	Competitive mechanism
Rogaine	Brand recognition and category leadership
Kirkland and other store brands	Price leadership
Perrigo and other contract manufacturers	Scalable private-label supply
Hims and Keeps	Telehealth acquisition and subscription retention
Roman and similar platforms	Physician-linked treatment bundles
Amazon and retailer brands	Search visibility and convenience
Compounded providers	Customized formulations, subject to applicable rules

The competitive risk is highest when consumers view all 5% minoxidil products as interchangeable. BosleyMD must create differentiation through formulation experience, professional association, diagnostics or bundled hair-loss services.

What licensing deals could create commercial value?

Licensing opportunities may involve:

• A propylene-glycol-free minoxidil vehicle.
• A low-residue foam technology.
• A precision scalp applicator.
• A combination product with another hair-loss active, subject to regulatory requirements.
• A digital adherence platform.
• A contract-manufacturing agreement with regional capacity.
• Retailer-exclusive packaging or dosage formats.
• International distribution rights.

The most valuable licensing target would be a platform that improves persistence and supports premium pricing across several products. A narrow patent covering one bottle or solvent ratio would have less commercial value unless it prevents direct substitution.

What generic launch scenarios exist?

Low-price generic entry

This is the base case. A new entrant markets a monograph-compliant 5% solution with conventional excipients. It competes primarily on price and search placement.

Premium foam substitution

A competitor launches a foam that avoids propylene glycol and emphasizes cosmetic acceptance. This scenario threatens BosleyMD if its product is a conventional solution.

Private-label retailer expansion

A large retailer introduces a low-price 5% minoxidil product. This can compress shelf pricing and reduce branded conversion.

Telehealth bundling

A telehealth provider includes minoxidil with finasteride, dutasteride, supplements or consultation services. The product becomes a customer-retention tool rather than a standalone margin product.

Formulation-led premium launch

A new product uses a novel vehicle, improved applicator or clinically tested tolerability benefit. This is the scenario most likely to support durable premium pricing, though the regulatory and evidence burden is higher.

How strong is the BosleyMD patent estate?

The estate should be treated as weak at the active-ingredient level and potentially moderate at the formulation, packaging or trademark level.

IP category	Indicative strength
Minoxidil molecule	Low
5% concentration	Low
Conventional solution excipients	Low
Foam vehicle	Moderate if claims are narrow and enforceable
Applicator design	Moderate
Packaging trade dress	Moderate
Brand trademark	Potentially strong against confusingly similar marks
Manufacturing know-how	Potentially valuable but confidential
Clinical differentiation	Stronger commercially if supported by data

The practical moat is likely to be brand and channel execution, not blocking patent rights.

What is the revenue exposure from generic competition?

Revenue exposure depends on whether BosleyMD sells the product as a premium standalone treatment or as part of a broader hair-loss ecosystem.

A standalone product is vulnerable to price erosion because:

• Minoxidil is widely available.
• Consumers can switch without physician involvement.
• The active ingredient is identical across many products.
• Retailers can introduce private-label alternatives.
• Subscription switching costs are low.

Bundling can reduce this exposure. A BosleyMD customer may remain with the brand if minoxidil is combined with consultation, hair transplantation services, diagnostic evaluation, supplements, shampoos or other recurring products.

The strongest commercial metrics are refill rate, discontinuation rate, average order value and conversion from topical treatment to higher-margin services.

Key Takeaways

• BosleyMD Extra Strength for Men is an OTC 5% topical minoxidil product, not a protected new chemical entity.
• The excipient strategy is central to differentiation because the active ingredient is commoditized.
• Liquid products generally prioritize low cost and established solubility using alcohol, propylene glycol and water.
• Foam products can improve cosmetic acceptance and may support propylene-glycol-free positioning.
• The main commercial opportunity is improved tolerability and adherence.
• Conventional Orange Book and Paragraph IV strategies are generally less relevant than OTC monograph compliance and formulation patent analysis.
• Patent value is more likely to reside in vehicles, applicators, packaging and manufacturing know-how than in minoxidil itself.
• Generic, private-label and telehealth competition creates high substitution risk.
• BosleyMD can defend premium pricing through sensory performance, professional-channel integration, subscription retention and differentiated packaging.
• The best licensing targets are platform technologies that improve scalp tolerability, drying time, delivery precision or adherence.

FAQs

Can BosleyMD use a propylene-glycol-free minoxidil formulation?

Yes, if the product maintains required quality, stability, labeling and OTC regulatory conditions. A propylene-glycol-free system would need an alternative solubilization strategy.

Is 5% minoxidil foam more commercially defensible than 5% solution?

Usually. Foam allows greater differentiation in drying time, residue, tolerability and packaging, although it also increases manufacturing and container costs.

Can a new excipient combination receive a patent?

Yes, but broad claims are difficult in a mature minoxidil field. Stronger protection generally requires a specific composition, measurable performance advantage and defensible distinction from prior art.

Does BosleyMD need an approved NDA for its OTC minoxidil product?

A qualifying product marketed under the FDA OTC hair-growth monograph can generally rely on the monograph framework rather than a conventional prescription NDA pathway.[1]

What is the most valuable commercial improvement for BosleyMD?

A clinically supported vehicle that reduces irritation and residue while preserving rapid drying and dose consistency would likely create the strongest premium opportunity.

References

1. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 347: Skin protectant drug products for over-the-counter human use, including products marketed for hair growth. Electronic Code of Federal Regulations.

2. U.S. Food and Drug Administration. (2024). Drug Facts labeling for over-the-counter drug products. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.